There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Recruiting
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to <12 with LN.
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
06/07/2024
Locations: Cincinnati Childrens Hospital, Cincinnati, Ohio
Conditions: Lupus Nephritis
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Recruiting
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients... Read More
Gender:
All
Ages:
Between 3 years and 29 years
Trial Updated:
06/07/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Choriocarcinoma, Suprasellar Germ Cell Tumor
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
Recruiting
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Carcinoma, Hepatocellular
Regulating Together in Tuberous Sclerosis Complex
Recruiting
The purpose of this study is to use a program called Regulating Together (RT), a remote, non-pharmacologic intervention to treat symptoms of emotion dysregulation in children and adolescents with Tuberous Sclerosis Complex (TSC) and TSC-Associated Neuropsychiatric Disorder (TAND).
Gender:
All
Ages:
Between 8 years and 17 years
Trial Updated:
06/07/2024
Locations: Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio
Conditions: TSC, Behavioral Symptoms
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Focal Epilepsy
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Recruiting
The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML in the pediatric population has the same pathogenesis, similar clinical characteristics and progression pattern as in adults.
Gender:
All
Ages:
Between 1 year and 18 years
Trial Updated:
06/07/2024
Locations: Cinn Children Hosp Medical Center, Cincinnati, Ohio
Conditions: Myeloid Leukemia, Philadelphia Positive
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Recruiting
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
06/07/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Irritability Associated With Autism Spectrum Disorder
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/07/2024
Locations: UC Health, LLC., Cincinnati, Ohio
Conditions: Multiple Sclerosis
Overlapping Pain Trajectory Study
Recruiting
The goal of this observational study is to learn about spatial and temporal nociceptive filtering in adolescents with chronic overlapping pain conditions (COPCs). The main questions it aims to answer are: If spatial and temporal filtering of nociceptive information is disrupted in youth with COPCs compared with youth with localized pain conditions and healthy controls. If disrupted nociceptive processing at baseline is associated with the transition from a single localized pain condition to COP... Read More
Gender:
All
Ages:
Between 10 years and 19 years
Trial Updated:
06/07/2024
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Migraine, Musculoskeletal Pain, Functional Abdominal Pain Disorders, Chronic Pain, Widespread Chronic Pain, Low Back Pain, Healthy Volunteers
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
Recruiting
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/07/2024
Locations: 89bio Clinical Study Site, Cincinnati, Ohio
Conditions: Severe Hypertriglyceridemia
Imatinib for Pain in Sickle Cell Anemia
Recruiting
In this protocol, the investigators propose to evaluate the biochemical effects of imatinib on sickle red blood cells (RBCs). Patients will be administered imatinib mesylate orally following the guidelines previously established for use of imatinib in other disorders. The biochemical effects of imatinib on sickle RBCs will be examined, including changes in their levels of band 3 tyrosine phosphorylation and the abundances of RBC-derived microparticles in their blood. In addition, the patients wi... Read More
Gender:
All
Ages:
Between 18 years and 25 years
Trial Updated:
06/07/2024
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Sickle Cell Disease
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: The Lindner Center, Cincinnati, Ohio
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus